Leerink Partners Cuts Price Target on Intersect ENT (XENT) to $14; Reiterates Outperform

After-Hours Stock Movers 11/02: (IQNT) (AUPH) (KTOS) Higher; (FIT) (DPLO) (FB) Lower (more...)

November 2, 2016 6:27 PM EDT

Today's After-Hours Moves

Inteliquent, Inc. (NASDAQ: IQNT) 33.6% HIGHER; entered into a definitive agreement to be acquired by an affiliate of GTCR LLC, a leading private equity firm, and merged with a subsidiary of Onvoy, LLC a fast-growing leader in Communications Enablement services. Under the terms of the agreement, Inteliquent stockholders of record will receive $23.00 in cash per share of common stock, which represents a 37% premium to Inteliquents closing stock price on November 1, 2016. The value of the transaction is approximately $800 million.

Fitbit (NYSE:... More

Intersect ENT (XENT) Tops Q3 EPS by 5c

November 2, 2016 4:48 PM EDT

Intersect ENT (NASDAQ: XENT) reported Q3 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $17.84 million.

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

... More

Unusual 11 Mid-Day Movers 11/2: (EGRX) (NVCR) (AVXS) Higher; (ADPT) (CEMP) (TNDM) Lower

November 2, 2016 12:55 PM EDT

Adeptus Health (NYSE: ADPT) 65.7% LOWER; reported Q3 EPS of $0.06, $0.50 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $89.99 million. In a separate press release issued today, Adeptus Health's Board of Directors appointed Gregory W. Scott as the company's Chairman.

Cempra (Nasdaq: CEMP) 57.5% LOWER; shares trading lower with FDA briefing documents posted today.

Tandem Diabetes Care®, Inc. (Nasdaq: TNDM) 57.0% LOWER;... More

Pre-Open Stock Movers 11/02: (PTN) (AVXS) (EGRX) Higher; (ADPT) (CEMP) (DXCM) Lower (more...)

November 2, 2016 9:18 AM EDT

Today's Pre-Open Stock Movers

Adeptus Health (NYSE: ADPT) 57.9% LOWER; reported Q3 EPS of $0.06, $0.50 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $89.99 million.

Palatin Technologies, Inc. (NYSE: PTN) 36.3% HIGHER; announced positive, statistically significant top-line results from the Reconnect Studies, its Phase 3 clinical trial program of lead drug candidate bremelanotide. The Reconnect Studies, investigating bremelanotide as an on-demand treatment for premenopausal women diagnosed with hypoactive sexual desire disorder ("HSDD"), met... More

UPDATE: JPMorgan Downgrades Intersect ENT (XENT) to Neutral

November 2, 2016 7:27 AM EDT

(Updated - November 2, 2016 10:38 AM EDT)

JPMorgan downgraded Intersect ENT (NASDAQ: XENT) from Overweight to Neutral with a price target of $16.00 (from $25.00). The change follows the release of the final HOPPS rule.

"After the close on Tuesday Medicare released the highly anticipated Hospital Outpatient Prospective Payment System (HOPPS) final rule. In what is seemingly a worst case for manufacturers, CMS finalized the bundled... More

Trading Radar for 11/2: Facebook (FB), Qualcomm (QCOM), Alibaba (BABA), Yelp (YELP), Allstate (ALL), Fitbit (FIT) Report

November 1, 2016 2:56 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:15am EDT

ADP Employment Change - Street sees 165k

Earnings:

1-800-FLOWERS.com (NYSE: FLWS) - consensus loss $0.23
Alibaba (NYSE: BABA) - consensus EPS $0.69
Alkermes plc (Nasdaq: ALKS) - consensus loss $0.06
Allergan (NYSE: AGN) - consensus EPS $3.65
AmerisourceBergen (NYSE: ABC) - consensus EPS... More